DMAA

#3442
Drugs Made In America Acquisition Corp. - Ordinary Shares
10.7 5 USD
0.00%
Market Price
Settore: Finanziario
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
10.75
10.75
Intervallo Annuale
10.40
10.76
Variazione giornaliera
-0.09%
Variazione Mensile
+0.47%
Variazione di 6 mesi
+2.73%
Variazione Annuale
+2.97%
Chiusura Precedente
10.7 6
Open
10.7 5
Minimo
10.7 5
Massimo
10.7 5
Volume
1
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Drugs Made In America Acquisition Corp. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Drugs Made In America Acquisition Corp. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Drugs Made In America Acquisition Corp. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Drugs Made In America Acquisition Corp. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Drugs Made In America Acquisition Corp. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Drugs Made In America Acquisition Corp. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Drugs Made In America Acquisition Corp. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Drugs Made In America Acquisition Corp. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Drugs Made In America Acquisition Corp. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Drugs Made In America Acquisition Corp. current report, Q1 FY2026
8-K

Drugs Made In America Acquisition Corp. current report, Q1 FY2026

Full document

Business Context and Reporting Period

Company: Drugs Made In America Acquisition Corp.
Filing Type: Form 8-K (Current Report)
Date of Report: March 6, 2026
Context: The Company is a Cayman Islands-based special purpose acquisition company (SPAC) listed on The Nasdaq Stock Market. This filing addresses "Other Events" regarding financial irregularities discovered at an affiliate entity.

Key Financial Metrics

Trust Account Balance: Approximately $241,292,436 as of March 6, 2026.
Revenue, Profit, Cash Flow, Margins, Debt: The filing text does not provide a clear value for these operational metrics as this is a current report regarding a specific event, not a periodic financial statement.

Material Changes and Events

  • Affiliate Irregularities: Between September 26, 2025, and December 31, 2025, the sponsor of an affiliate (Drugs Made In America Acquisition II Corp.) made improper withdrawals from the affiliate's working capital account.
  • Trust Account Status: The Company's Board of Directors confirmed that these irregularities did not extend to the Company's own Trust Account.

Management Commentary and Risks

Management Action: Upon learning of the affiliate's irregularities, the Board immediately took action to verify the integrity of the Company's Trust Account.
Confirmation: Management confirms the Trust Account remains intact with the balance noted above.
Risks: The filing highlights governance risks associated with affiliate entities and sponsor conduct, though the Company's primary asset (the Trust Account) appears unaffected.

Investor Verification Checklist

  • Verify the exact nature and amount of the "improper withdrawals" at the affiliate (Drugs Made In America Acquisition II Corp.).
  • Confirm whether the affiliate's sponsor has been replaced or if legal action is being pursued.
  • Review the Company's internal controls to ensure no similar access exists for the Company's own working capital accounts.
  • Monitor for any future filings regarding the affiliate's status and potential impact on the Company's reputation or merger prospects.